Sigma Of Australia Inks Due-Diligence Pact With Suitor Aspen
This article was originally published in PharmAsia News
Executive SummaryAustralia's Sigma Pharmaceuticals moved closer to its acquisition by South Africa's Aspen Pharmacare as the two firms agreed on due-diligence procedures that could lead to closing the $591 million deal
You may also be interested in...
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.
The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.